Abstract 4287
Background
For patients with mCRC that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. In these secondary analyses of the OZONE study, aflibercept + FOLFIRI safety and efficacy was evaluated for sub-populations of patients with mCRC.
Methods
OZONE is a prospective, multicentre, observational, non-comparative study evaluating patients receiving aflibercept + FOLFIRI in the clinical setting, for 24 months from aflibercept initiation or until death. Patients were grouped according to: age (≥ 65 years vs < 65 years); renal (CrCl ≤ 80 mL/min) or hepatic (bilirubin > UNL or AST/ALT > 1.5 UNL) impairment; number and type of prior anti-cancer therapy.
Results
From the overall population (N = 766), there were 370 patients aged ≥ 65 years. All grade asthenia (43.5% vs 35.9%) and decreased appetite (25.4% vs 20.2%) occurred more frequently (≥ 5%) in patients aged ≥ 65 vs < 65 years. There were 256 patients with CrCl ≤ 80 mL/min, of which 43 had CrCl < 50 mL/min. Renal function did not influence treatment-emergent adverse events (TEAEs). Grade ≥ 3 TEAEs were reported in 76.7%, 67.1% and 67.9% of patients with CrCl < 50 mL/min, CrCl 50–80 mL/min, and CrCl > 80 mL/min, respectively. There were 129 patients with impaired liver function. All grade constipation and haemorrhage were more frequent in patients with impaired liver function vs those without (23.3% vs 14.2% and 37.2% vs 30.1%, respectively). There were 449 patients previously treated with bevacizumab. Only fatigue occurred more frequently in patients with prior bevacizumab vs those without (23.8% vs 17.0%). Efficacy multivariate analyses showed that treatment with aflibercept + FOLFIRI favoured patients without vs with hepatic impairment (median overall survival [OS] 13.7 vs 8.7 months; p < 0.001) and without vs with prior use of bevacizumab (median OS 16.6 vs 10.6 months; p < 0.001).
Conclusions
Subgroup analyses of the OZONE study did not reveal major differences in the safety profile according to age, renal or hepatic status, or prior bevacizumab status. These results suggest that aflibercept may be a treatment option for these subgroups of patients. Funding: Sanofi.
Clinical trial identification
ENCEPP/SDPP/4836.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
I. Chau: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli-Lilly; Advisory / Consultancy: Bristol Meyers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (self): Merck-Serono; Advisory / Consultancy: Five Prime Therapeutics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Oncologie International; Advisory / Consultancy: Pierre Fabre; Research grant / Funding (self): Janssen-Cilag; Research grant / Funding (self): Sanofi Oncology. P. García-Alfonso: Advisory / Consultancy: Amgen; Advisory / Consultancy: Bristol Meyers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy: Sanofi Oncology; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Servier. Z. Linke: Advisory / Consultancy, Advisory Board- Oncologic days in Bratislava, Slovakia, 2016, 2017, 2018 and Prague in 2018.: Sanofi; Speaker Bureau / Expert testimony, Lecture- Prague Onco 2019: Merck; Non-remunerated activity/ies, ESMO 2017: Roche. A. Ruiz-Casado: Research grant / Funding (self): Sanofi; Research grant / Funding (self): Servier; Research grant / Funding (self): Amgen; Research grant / Funding (self): Merck; Research grant / Funding (self): Lilly; Research grant / Funding (self): Roche; Research grant / Funding (self): Medtronic; Research grant / Funding (self): BTG. E. Polo Marques: Research grant / Funding (self): Roche; Research grant / Funding (self): Amgen; Research grant / Funding (self): Sanofi; Research grant / Funding (self): Merck. T. Cartwright: Research grant / Funding (self): Amgen; Research grant / Funding (self): Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract